Foghorn Therapeutics welcomes Ian Smith to its Board of Directors

– USA, MA –  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27.

“We welcome Ian to the Foghorn Board,” said Board chairmam, Dr. Doug Cole. “His experience building valuable biotech businesses will help us to deliver on the enormous potential of drugs based on chromatin dysregulation.”

“Ian is a proven biotechnology leader with a diverse skill set, and I am excited to welcome him to our Board at this important time in the company’s evolution,” said CEO, Adrian Gottschalk. “Ian has been advising the company since early 2020 on various initiatives including business development and equity financing strategies as well as company progression and development. The addition of Ian to our Board brings significant business experience and capital formation expertise to our Company.”

About Ian Smith

Mr. Smith is currently the Executive Chairperson of Viacyte, Inc. He was previously COO at Vertex Pharmaceuticals, Inc. Before joining Vertex in 2001, Mr. Smith served as a partner in the Life Science and Technology Practice of the accounting firm Ernst & Young LLP. He also serves as Chairman of the Board of Solid Biosciences, as a board member of AavantiBio Inc., and as a Senior Advisor to Bain Capital Life Sciences.

“I believe in a precision biology approach that focuses on the cause of disease; Foghorn’s focus on the chromatin regulatory system and its causal role in a broad range of serious diseases has the potential to create significant therapeutic breakthroughs,” commented Ian Smith. “I am pleased to join the Board and look forward to working with my fellow Board members, Adrian, and the Foghorn leadership team.”

About Foghorn Therapeutics

Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team